Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- DPP-4 Inhibitors Gain Traction, Boosting Diabetes Market by 15.5%: IMS Japan
May 25, 2012
- Zeria Projects 19% Increase in Asacol Sales to 12.2 Billion Yen in FY2012
May 25, 2012
- Japanese Ethical Drug Market Expands by 5.5% to 9.5348 Trillion Yen: IMS Japan
May 25, 2012
- Takeda Files MAA for Alogliptin in Europe
May 25, 2012
- National Cancer Center, Daiichi Sankyo Conclude Comprehensive Joint Research Agreement for Cancer Drug Discovery
May 24, 2012
- RIKEN and Takeda Open Collaboration Center for Developing Drug Discovery Technology for CNS Diseases
May 24, 2012
- Daiichi Sankyo Completes Patient Recruitment in Overseas PIII Trial of ARQ 197 for NSCLC
May 24, 2012
- Xarelto No. 1, Prazaxa Ranks 2nd in Call Frequency in HP Market: Rep Track April Survey
May 24, 2012
- Meiji HD Targets Pharmaceuticals Segment Sales at 140 Billion Yen in FY2014
May 23, 2012
- Four Major Listed Dispensing Pharmacies Post Record Performance in FY2011
May 23, 2012
- Myslee Is Most Prescribed Insomnia Drug: Survey
May 23, 2012
- AnGes MG to Allocate Shares Worth 200 Million Yen to Shionogi to Develop NF-κB Decoy Oligo
May 23, 2012
- 11 Leading Foreign-Affiliated Drug Makers Report 12% Growth in Sales in 2011 Driven by New Drugs
May 23, 2012
- NDA Filed for Anti-Androgen Drug MDV3100 in the US: Astellas
May 23, 2012
- Japan Vaccine to Make All-Out Effort,“Invest All Resources” in Cervical Cancer, Rotavirus Vaccines
May 22, 2012
- Sandoz to Copromote Somatropin with Nipro Pharma
May 22, 2012
- Towa to Review Existing Products for Improved Competitiveness, Starting with 70 APIs
May 22, 2012
- Chugai to Make CNS Its Strategic Field; 3 Compounds in Pipeline: President Kosaka
May 21, 2012
- Operating Profits Up 4.2%, Business Expansion Slows Down in FY2011: Major Generics Manufacturers
May 21, 2012
- Hisamitsu Files for Transdermal Oxybutynin for Overactive Bladder
May 21, 2012
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…